Actinogen Medical Ltd Total Assets
Actinogen Medical Ltd total assets. Based on the latest financial reports, Actinogen Medical Ltd (ACW) holds total assets worth AU$24.48 Million AUD (≈ $17.32 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Actinogen Medical Ltd for the company's overall valuation and market capitalisation.
Total Assets of Actinogen Medical Ltd (2006–2025)
Total assets of Actinogen Medical Ltd from 2006 to 2025. This chart illustrates how Actinogen Medical Ltd's total assets have evolved over time, based on quarterly financial data. See ACW stock price for real-time trading data and today's change.
Actinogen Medical Ltd - Asset Composition Analysis
Actinogen Medical Ltd Total Assets Breakdown (June 2025)
Actinogen Medical Ltd total assets breakdown as of June 2025. Actinogen Medical Ltd's total assets of AU$24.48 Million consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 67.4% |
| Accounts Receivable | AU$5.80 Million | 23.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$1.78 Million | 7.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Actinogen Medical Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Actinogen Medical Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Actinogen Medical Ltd's current assets represent 91.6% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 67.4% of total assets in 2025, down from 83.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 23.7% of total assets.
Actinogen Medical Ltd Competitors by Total Assets
Key competitors of Actinogen Medical Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Actinogen Medical Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.76 | 13.91 | 10.98 |
| Quick Ratio | 3.76 | 13.83 | 10.98 |
| Cash Ratio | 0.00 | 5.32 | 4.79 |
| Working Capital | AU$16.47 Million | AU$17.52 Million | AU$7.42 Million |
Actinogen Medical Ltd - Advanced Valuation Insights
This section examines the relationship between Actinogen Medical Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.37 |
| Latest Market Cap to Assets Ratio | 3.77 |
| Asset Growth Rate (YoY) | 14.9% |
| Total Assets | AU$24.48 Million |
| Market Capitalization | $92.21 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Actinogen Medical Ltd's assets at a significant premium (3.77x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Actinogen Medical Ltd's assets grew by 14.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Actinogen Medical Ltd (2006–2025)
The table below shows the annual total assets of Actinogen Medical Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$24.48 Million ≈ $17.32 Million |
+14.87% |
| 2024-06-30 | AU$21.31 Million ≈ $15.08 Million |
+40.13% |
| 2023-06-30 | AU$15.21 Million ≈ $10.76 Million |
-34.74% |
| 2022-06-30 | AU$23.31 Million ≈ $16.49 Million |
+26.81% |
| 2021-06-30 | AU$18.38 Million ≈ $13.00 Million |
+53.97% |
| 2020-06-30 | AU$11.94 Million ≈ $8.45 Million |
-26.42% |
| 2019-06-30 | AU$16.22 Million ≈ $11.48 Million |
-10.01% |
| 2018-06-30 | AU$18.03 Million ≈ $12.75 Million |
+76.55% |
| 2017-06-30 | AU$10.21 Million ≈ $7.22 Million |
-21.16% |
| 2016-06-30 | AU$12.95 Million ≈ $9.16 Million |
-16.88% |
| 2015-06-30 | AU$15.58 Million ≈ $11.02 Million |
+1134.74% |
| 2014-06-30 | AU$1.26 Million ≈ $892.76K |
+357.70% |
| 2013-06-30 | AU$275.67K ≈ $195.06K |
-40.82% |
| 2012-06-30 | AU$465.80K ≈ $329.58K |
-59.17% |
| 2011-06-30 | AU$1.14 Million ≈ $807.19K |
-14.98% |
| 2010-06-30 | AU$1.34 Million ≈ $949.44K |
-33.16% |
| 2009-06-30 | AU$2.01 Million ≈ $1.42 Million |
-31.75% |
| 2008-06-30 | AU$2.94 Million ≈ $2.08 Million |
+997.58% |
| 2007-06-30 | AU$268.00K ≈ $189.63K |
+405.66% |
| 2006-06-30 | AU$53.00K ≈ $37.50K |
-- |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more